Commentary
Acute cardiogenic pulmonary edema (ACPE) is common, costly, and lethal, with associated mortality rates of 10-20% [2, 3] . When severe, it is traditionally managed with endotracheal intubation and mechanical ventilation. Interest in using noninvasive ventilation (NIV) in the treatment of ACPE has grown since the early work of Rasanen and colleagues from 1985 [4] . Whether delivered in the form of continuous positive airway pressure (CPAP) or noninvasive intermittent positive pressure ventilation (NIPPV), NIV improves physiologic parameters in patients with ACPE, including decreasing respiratory acidosis, respiratory rate, work of breathing, heart rate, and sensation of dyspnea [5, 6] . It may also reduce rates of endotracheal intubation [5, 7, 8] . A variety of clinical trials have been conducted in this area, though most were small, single-centered studies lacking power to determine if NIV reduces mortality [4, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Recent systematic reviews and meta-analyses suggest that indeed it may [5-8]. However, the small size of included studies and variation in study populations, interventions, and endpoints leave some doubt to the generalizability of these fi ndings.
To address these uncertainties, Gray and colleagues performed a large, multi-center, randomized controlled trial in 1069 patients with ACPE to determine whether NIV improves survival and if NIPPV is superior to CPAP [1]. Th eir trial, referred to as the 3CPO (Th ree interventions in Cardiogenic Pulmonary Oedema) study, was completed in 26 emergency departments in the UK. Patients were randomized to three groups: standard oxygen therapy, CPAP (5 -15 cm of H 2 O), or NIPPV (8/4 to 20/10 cm of H 2 O). Th ere were no diff erences in baseline characteristics, comorbid conditions, or the receipt of standard medical treatments, such as diuretics, nitrates and opiates. Th ough NIV did provide more rapid improvement in respiratory distress and metabolic distur bances, there were no diff erences in clinical outcomes, including mortality, rates of endotracheal intubation, length of stay, or myocardial infarction. Th ere were no diff erences between CPAP and NIPPV in any of the primary or secondary outcomes. Th e authors conclude that in patients with ACPE, noninvasive ventilation produces more rapid resolution of metabolic abnormalities and respiratory distress but has no eff ect on short-term mortality.
Th is study has a number of strengths, most important of which is that it was the largest randomized trial to date in this area, enrolling more patients than the combined number of patients from all studies included in prior meta-analyses [5] [6] [7] [8] . Some limitations deserve mention. Th is was a study of patients presenting to the emergency department and therefore may not apply to the use of NIV in the pre-hospital setting or to those patients who develop ACPE later in their hospital stay. Patients were excluded if they required lifesaving or emergency intervention, a group that might have benefi ted most from NIV. Th e most concerning limitation, however, is the considerable cross-over between groups and the lack of objective criteria for intubation. Fifty-six patients who failed standard oxygen treatment were rescued with NIV. Assuming that all 56 would have required intubation, the control 7-day intubation rate would have increased from 2.8% to 18.0%, which would have made the intubation rate in the standard oxygen treatment group signifi cantly greater than the NIV group (2.9%).
Recommendation
Th e results of this study should not limit the use of NIV in the setting of ACPE. NIV leads to more rapid improvement of symptoms of respiratory distress and metabolic disturbances as compared to standard oxygen therapy. We further argue that based on this study, one should not draw a conclusion that NIV is ineff ective in preventing intubation. Th ough NIV has not been convincingly shown to reduce mortality, it remains a valuable adjunct in the treatment of ACPE.
